ARTICLE | Clinical News
ABX-CBL: Phase II/III
February 24, 2003 8:00 AM UTC
The companies discontinued development of ABX-CBL after the compound failed to meet the primary endpoint of increased survival at 180 days compared to Atgam anti-thymocyte globulin. The Phase II/III ...